We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
An insider trade (Form 4) was filed.
A material-event filing was submitted. Check the category (guidance / executives / M&A, etc.).
신규 편입 · 포트폴리오 비중 0.02%
신규 편입 · 포트폴리오 비중 0.13%
An insider trade (Form 4) was filed.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
A quarterly report was filed. Review revenue/cost trends and guidance changes.
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
Consensus vs. actual, and revenue trend
Consensus PT $389.43 · 26 analysts
Stored first · Google News · Yahoo Finance (English)
BTIG Research Adjusts Stryker Price Target to $371 From $379, Maintains Buy Rating - marketscreener.com
BTIG Research Adjusts Stryker Price Target to $371 From $379, Maintains Buy Rating marketscreener.com
BTIG Research Adjusts Stryker Price Target to $371 From $379, Maintains Buy Rating
Piper Sandler reiterates Stryker stock rating on Mako strength - Investing.com
Piper Sandler reiterates Stryker stock rating on Mako strength Investing.com
Comprehensive Nerve Repair Biomaterials Market Report Published, Profiles Medtronic, Stryker, Boston Scientific, and 20 Other Key Players - Yahoo Finance
Comprehensive Nerve Repair Biomaterials Market Report Published, Profiles Medtronic, Stryker, Boston Scientific, and 20 Other Key Players Yahoo Finance
Comprehensive Nerve Repair Biomaterials Market Report Published, Profiles Medtronic, Stryker, Boston Scientific, and 20 Other Key Players
ISRG to Report Q2 Results Next Week: Should You Buy the Stock Now?
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 30. | After market close (AMC) | $3.48 | — | — | $6.58B | — | Scheduled |
| FY2026 Q1 | 2026. 05. 11. | Time TBD | — | $1.69 | — | — | $5.87B | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $6.35 | — | — | $16.16B | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $4.19 | — | — | $10.67B | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 05. | Truist Securities | — | Maintain | Hold → Hold | — | Truist Securities: Hold |
| 2026. 05. 04. | Barclays | — | Maintain | Overweight → Overweight | — | Barclays: Overweight |
| 2026. 05. 02. | Canaccord Genuity | — | Maintain | Buy → Buy | — | Canaccord Genuity: Buy |
| 2026. 05. 02. | JP Morgan | — | Maintain | Overweight → Overweight | — | JP Morgan: Overweight |
| 2026. 05. 01. | Evercore ISI Group | — | Maintain | Outperform → Outperform | — | Evercore ISI Group: Outperform |
| 2026. 05. 01. | Wells Fargo | — | Maintain | Overweight → Overweight | — | Wells Fargo: Overweight |
As of FY2018Q3 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 469,215 | $154.18M | 0.13% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 89,028 | $31.29M | 0.05% | — | New position |
| 3 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 25,240 | $8.29M | 0.02% | — | New position |